Trial Profile
A Dose-finding Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs F16 IL2 fusion protein (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Philogen
- 06 Oct 2023 Status changed from active, no longer recruiting to discontinued because new agents for the same indication impacted on patients' recruitment.
- 19 Apr 2022 Planned End Date changed from 1 Dec 2019 to 1 Sep 2022.
- 19 Apr 2022 Planned primary completion date changed from 1 Mar 2019 to 1 Sep 2022.